Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Sezione di Ematologia Dipartimento di Scienze Biomediche e Terapie Avanzate Azienda Ospedaliera-Universitaria “Arcispedale S. Anna”, Ferrara, Italia
The combination acetominophen/tramadol implies the use of two molecules which are different in the pharmacological structure but share a biological similarity in kinetics. Their respective actions are directed to different components of the nociceptive afference. Hematological clinical practice daily challenges diseases in with pain may be a very important symptom, ranging from acute leukemia to the common effects of certain chemotherapy regimens. Multiple myeloma gives one of the best example of a disease in which pain can be inflammatory (the compression of a nerve root) or neuropathic (demyelinating process) in origin. The use of acetaminophen/tramadol combination in the common ward or outward activity with myeloma patients indicates how it is possible to reach a good control of chronic pain with a minimum overlapping of the toxicities related to the primary disease as well as to the specific treatment. Furthermore, acetaminophen/tramadol combination is extre-mely useful also in those clinical situations in which a short term pain control is needed, particularly for the optimal safety profile.